公开(公告)号：US20060167220A1

公开(公告)日：2006-07-27

申请号：US11321035

申请日：2005-12-28

申请人： Richard Dauer ,  Christina Evanson ,  Paul Friedrich ,  Hafez Hafezzadeh ,  Ramakrishna Nalitham ,  Stephen Schneider ,  Mark Schwindt ,  Roger Snyder ,  Joseph White ,  Gregory Withers

发明人： Richard Dauer ,  Christina Evanson ,  Paul Friedrich ,  Hafez Hafezzadeh ,  Ramakrishna Nalitham ,  Stephen Schneider ,  Mark Schwindt ,  Roger Snyder ,  Joseph White ,  Gregory Withers

IPC分类号： C07K14/00

CPC分类号： C07K14/005 ,  C07K1/145 ,  C07K1/303 ,  C07K14/605 ,  C12N2740/16122

摘要： The formation of inactive, insoluble forms of peptide can be minimized or, alternatively, inactive, insoluble forms of peptide compounds, if present, can be converted into more physiologically active, soluble forms by dissolving peptide samples in aqueous base and then acidifying the aqueous mixture to precipitate the peptide in the presence of at least one of a salt and a co-solvent. Preferably, both a salt and co-solvent are present. By carrying out the precipitation relatively rapidly (at least in a first stage of acidifying in which the pH of the alkaline medium is reduced to a pH in the range of 6 to 7.5, after which acidification to a final desired pH, e.g., 3 to 6, can occur more slowly) at relatively low temperature, the dissolution characteristics of the resultant precipitated peptide are even further improved. The process is robust, consistent, and suitable for commercial scale manufacture of peptides.

摘要翻译： 通过将肽样品溶解在碱性水溶液中，然后使含水混合物酸化，可以使肽的无活性，不溶性形式形成，或者如果存在的话，可以通过将肽化合物的不溶形式（如果存在的话）转化为更具生理活性的可溶形式， 以在盐和共溶剂中的至少一种的存在下沉淀肽。 优选地，存在盐和共溶剂。 通过相对快速地进行沉淀（至少在第一阶段的酸化中，将碱性介质的pH降低至6至7.5范围内的pH，然后酸化至最终所需的pH，例如3至 6，可以更慢地发生），在所得沉淀肽的溶解特性进一步提高。 该方法稳健，一致，适用于商业规模生产肽。

公开(公告)号：US20070265490A1

公开(公告)日：2007-11-15

申请号：US11679487

申请日：2007-02-27

申请人： Robert Smith ,  Roger Snyder ,  Adrian Kantrowitz ,  Allen Kantrowitz

发明人： Robert Smith ,  Roger Snyder ,  Adrian Kantrowitz ,  Allen Kantrowitz

IPC分类号： A61M1/10

CPC分类号： A61M1/1072 ,  A61M1/1008 ,  A61M1/1037 ,  A61M1/106 ,  A61M1/122 ,  A61M1/125

摘要： A blood pump for placement in an incision in an aorta is provided that after placement contacts blood passing through the aorta. The pump inflates and deflates in order to provide left ventricular assistance. The pump has an elongated shell with a generally elliptical shape, an outer convex surface and an inner concave surface. A peripheral side edge located between the inner and outer surfaces terminates in a bead edge. A passage is provided through the shell to provide fluid communication between the outer surface and inner surface. A flexible airtight membrane has a membrane edge bonded to the outer shell surface adjacent to the bead edge to form an enclosed internal chamber in fluid communication with the passage. Preforming the membrane edge looped with a maximum linear span of curvature that is greater than a maximal transverse linear extent of the bead edge, membrane operational wear during inflation and deflation cycles is reduced in the region around the bead edge. A process of forming a blood pump with a membrane preform is provided that includes placing an airtight membrane around a platen having a platen edge bead with a curvature of maximal transverse linear extent and a platen footprint substantially identical to a footprint of the blood pump shell. By heat setting the membrane, a looped membrane edge is formed as complementary to the curvature of the platen edge bead to yield a membrane preform. The membrane preform is secured to the outer surface of the shell having a bead edge of maximum linear extent less than the curvature of the looped membrane edge.

摘要翻译： 提供用于放置在主动脉切口中的血泵，其在放置后接触通过主动脉的血液。 泵充气和放气以提供左心室辅助。 泵具有大致椭圆形的细长壳体，外凸面和内凹面。 位于内表面和外表面之间的周边侧边缘终止于边缘。 通过壳体提供通道以在外表面和内表面之间提供流体连通。 柔性密封膜具有与胎圈边缘相邻的外壳表面结合的膜边缘，以形成与通道流体连通的封闭内部室。 预先形成最大线性曲率跨度的膜边缘，其大于胎圈边缘的最大横向线性范围，在充气和放气周期期间的膜操作磨损在珠边缘周围的区域减小。 提供了一种形成具有膜预制件的血液泵的过程，其包括将气密膜放置在具有最大横向线性范围的曲率的台板边缘珠的压板上，和与血泵壳的占地面积基本相同的压板盖板。 通过热定形膜，形成环形膜边缘，以与压板边缘珠的曲率互补以产生膜预制件。 膜预制件被固定到外壳的外表面，其具有小于环形膜边缘的曲率的最大线性范围的边缘边缘。